The Learning about Expanded Access and Potential of the LNG-IUS (LEAP LNG-IUS) initiative generates timely, actionable evidence to help determine if and how expanded access to the levonorgestrel intrauterine system (LNG-IUS) — a long-acting contraceptive also known as the levonorgestrel intrauterine device (LNG-IUD) or hormonal IUD — could increase contraceptive use and continuation rates in sub-Saharan Africa. The initiative will generate evidence to better understand the potential demand for the LNG-IUS, experiences among users and providers, and continuation rates and cost-effectiveness compared with other long-acting contraceptive methods.
FHI 360 is implementing the initiative and partnering with Population Services International (PSI), Society for Family Health Nigeria and Zambia, and WCG (formerly known as WomanCare Global) with support from the Bill & Melinda Gates Foundation. Research is being conducted in Kenya, Nigeria and Zambia, where pilot introduction projects are being implemented by partners with funding from the U.S. Agency for International Development (USAID).
The evidence generated through the LEAP LNG-IUS initiative will help improve decision-makers’ understanding of the potential value of adding the LNG-IUS to the contraceptive method mix in sub-Saharan Africa and could help inform national introduction and scale-up plans.
The project is part of FHI 360’s Contraceptive Technology Innovation portfolio. For more information about the project, please contact the Contraceptive Technology Innovation team.
